Cantor Fitzgerald initiated coverage on Rezolute with a new price target
$RZLT
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald initiated coverage of Rezolute with a rating of Overweight and set a new price target of $9.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/5/2024 | $12.00 | Outperform | Wedbush |
| 8/27/2024 | $11.00 | Buy | Guggenheim |
| 7/17/2024 | $13.00 | Buy | BTIG Research |
| 6/4/2024 | $14.00 | Buy | Craig Hallum |
| 4/9/2024 | $8.00 | Buy | Maxim Group |
| 8/2/2022 | $17.00 | Buy | Canaccord Genuity |
| 6/15/2022 | $9.00 | Overweight | Cantor Fitzgerald |
| 11/29/2021 | $30.00 → $17.00 | Buy | Canaccord Genuity |
4 - Rezolute, Inc. (0001509261) (Issuer)
4 - Rezolute, Inc. (0001509261) (Issuer)
4 - Rezolute, Inc. (0001509261) (Issuer)
8-K - Rezolute, Inc. (0001509261) (Filer)
8-K - Rezolute, Inc. (0001509261) (Filer)
S-8 - Rezolute, Inc. (0001509261) (Filer)
Wedbush initiated coverage of Rezolute with a rating of Outperform and set a new price target of $12.00
Guggenheim initiated coverage of Rezolute with a rating of Buy and set a new price target of $11.00
BTIG Research initiated coverage of Rezolute with a rating of Buy and set a new price target of $13.00
SC 13G/A - Rezolute, Inc. (0001509261) (Subject)
SC 13G/A - Rezolute, Inc. (0001509261) (Subject)
SC 13G/A - Rezolute, Inc. (0001509261) (Subject)
Breakthrough Therapy Designation granted based on key positive data from the Phase 2b (RIZE) study and current unmet medical need in congenital hyperinsulinism (HI) Ersodetug continues to advance in clinical development as a potential treatment for hypoglycemia caused by all forms of hyperinsulinism; topline sunRIZE data expected second half of this year REDWOOD CITY, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrou
REDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced that its compensation committee has approved the issuance of One Hundred and Fifty Thousand (150,000) shares of its common stock as an inducement award (the "Inducement Award") permitted under Nasdaq Rule 5635(c)(4) to its new Senior Vice President of Global Product Supply. The Inducement Award was granted on November 30, 2024 and was priced at our closing price on November 29, 2024. The Inducement Award will vest 25% one year aft
REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ersodetug for the treatment of hypoglycemia due to tumor HI. "FDA's granting of Orphan Drug Designation is a recognition of the serious unmet need patients with tumor hyperinsulinism face and validates the potential significant benefit that ersodetug can provide," said Susan Stewart, J.D, Chief Regulatory Officer of Rezolute. "Tumor HI requir
4 - Rezolute, Inc. (0001509261) (Issuer)
4 - Rezolute, Inc. (0001509261) (Issuer)
4 - Rezolute, Inc. (0001509261) (Issuer)
REDWOOD CITY, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced the addition of Daron Evans, MS, MBA, to its leadership team as Chief Financial Officer as well as the grant of share options as a material inducement for his appointment (the "Inducement Grant"). About Mr. Evans "This is a pivotal year for Rezolute as we initiated our Phase 3 clinical study for RZ358 in congenital hyperinsulinism and anticipate reporting topline data from our Phase 2 study for RZ402 in diabetic macular edema in the secon
REDWOOD CITY, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced that the Company has initiated dosing in a Phase 1b multiple-ascending dose study of RZ402, Rezolute's investigational oral plasma kallikrein inhibitor (PKI) for the treatment of diabetic macular edema (DME). Rezolute also announced the appointment of ophthalmology expert and key opinion leader, Dr. Rajat Agrawal, MD, MS, as Vice President, Clinical Development to lead the RZ402 clinical development program. "The Phase 1b study will evaluate the
REDWOOD CITY, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced the addition of Davelyn Hood, MD, to its leadership team as Director, Scientific and Patient Affairs. In her new role, Dr. Hood will be a key member of the team in furthering the development of RZ358, Rezolute's monoclonal antibody currently being evaluated in a Phase 2b clinical trial to treat congenital hyperinsulinism, a rare disease that is the most common cause of persistent low blood sugars in children. "Dr. Hood is an ideal addition to our
Phase 3 clinical study of RZ358 underway in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Benefit shown in individual patient cases with RZ358 for tumor-associated hyperinsulinism (taHI) under Expanded Access Program (EAP); drives alignment with FDA on unmet need and potential to move into late-stage clinical development to further evaluate RZ358 in this population REDWOOD CITY, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial re
REDWOOD CITY, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced its financial results for the first quarter of fiscal 2024 ended September 30, 2023. "We are on track to commence our Phase 3 study for RZ358 to treat congenital hyperinsulinism prior to year-end and are delighted to have recently obtained PRIME eligibility from the European Medicines Agency for this indication," said Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute. "We also anticipate completing enrollment this quarter for our o
REDWOOD CITY, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt treatment paradigms for devastating metabolic diseases, today announced its financial results for the fourth quarter and full fiscal year ended June 30, 2023. "We are delighted that we are poised to initiate sunRIZE – our Phase 3 study of RZ358, which we hope will bring us one step closer to making this therapy available to patients and their families suffering from congenital hyperinsulinism. We are also anticipating results from our Phase 2 study of RZ402 in the first quarter of 20